APN1125 / CoMentis, Alpharmagen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
APN1125 / CoMentis, Alpharmagen
NCT02331433: Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

Completed
1
58
US
APN1125, Placebo
CoMentis, Alpharmagen, Inc.
Schizophrenia
11/15
12/15

Download Options